CMS Seeks Lab Input on Sweeping Anti-Fraud Rules Targeting Genetic Testing Overspending

With genetic test spending under the microscope, CMS is asking labs to help shape future anti-fraud rules—before formal proposals are drafted. This proactive outreach by the Centers for Medicare and Medicaid Services (CMS) signals an intensifying focus on safeguarding the integrity of federal healthcare programs, particularly concerning high-cost clinical diagnostic testing. Clinical laboratory leaders, compliance officers, and revenue cycle teams faced a critical, albeit narrow, window to influence this significant new federal initiative, as the agency’s comment period for its "CRUSH" Request for Information (RFI) closed on March 30. The initiative, formally known as Comprehensive Regulations to Uncover Suspicious Healthcare, outlines CMS’s intent to pursue broad regulatory changes designed to bolster program integrity across Medicare, Medicaid, and Medicare Advantage, with a pointed emphasis on the burgeoning sector of genetic and molecular diagnostics.

The Genesis of CRUSH: Addressing Systemic Fraud and Fiscal Strain

The publication of the CRUSH RFI in the Federal Register on February 27, 2026, was not an isolated event but rather a strategic move by CMS in response to escalating concerns over healthcare fraud, waste, and abuse. The U.S. healthcare system, particularly its federal programs, loses billions of dollars annually to fraudulent schemes, a burden that ultimately impacts taxpayers and the quality of care available to beneficiaries. For years, various government agencies, including the Department of Justice (DOJ), the Office of Inspector General (OIG), and CMS itself, have waged campaigns against healthcare fraud, resulting in numerous enforcement actions and substantial recoveries. However, the sheer scale and evolving sophistication of fraudulent activities necessitate continuous adaptation of regulatory frameworks.

Genetic testing has emerged as a particularly vulnerable area within the diagnostic landscape. The rapid advancements in genomic science have led to the development of numerous complex and often high-cost molecular assays, promising personalized medicine and improved patient outcomes. However, this innovative frontier has also attracted unscrupulous actors seeking to exploit the intricacies of billing, the lack of widespread understanding among patients and even some clinicians, and the potential for substantial reimbursement. Prior enforcement actions have frequently highlighted schemes involving unsolicited genetic testing, often targeting seniors with misleading promises, performing medically unnecessary tests, and billing federal programs for services that were never ordered by a treating physician or lacked medical necessity. These schemes not only drain public funds but also expose vulnerable patients to privacy risks and potentially inappropriate medical advice based on unverified test results.

CMS’s mandate is clear: to ensure the financial solvency and integrity of Medicare, Medicaid, and Medicare Advantage programs while ensuring beneficiaries have access to necessary medical services. The CRUSH initiative underscores the agency’s commitment to fulfilling this mandate by proactively seeking stakeholder input before drafting formal rules, a practice designed to foster more effective and less disruptive regulations. This early engagement is critical, as it allows legitimate laboratories and healthcare providers to articulate operational realities, potential unintended consequences of proposed rules, and offer constructive solutions based on their frontline experience.

A Deep Dive into the CRUSH Initiative’s Scope and Ambitions

The "Comprehensive Regulations to Uncover Suspicious Healthcare" (CRUSH) initiative is more than just a crackdown on a specific type of fraud; it represents a holistic strategy to fortify the integrity of federal healthcare programs. The RFI, as a preliminary step, serves as a vital information-gathering tool, allowing CMS to solicit broad feedback from a diverse array of stakeholders, including clinical laboratories, physicians, patient advocacy groups, technology developers, and other payers. This consultative approach is intended to inform the agency’s understanding of the current fraud landscape, identify existing regulatory gaps, and explore innovative solutions.

Central to the RFI are several key areas of inquiry that shed light on CMS’s strategic thinking:

New Regulatory Authorities: CMS is exploring what additional legislative or regulatory powers might be necessary to enhance its ability to detect and prevent fraud more effectively. This could range from stricter enrollment requirements for providers to expanded authority for data sharing and enforcement.
Advanced Analytics Tools: The agency is keenly interested in leveraging cutting-edge data analytics, including artificial intelligence (AI) and machine learning (ML), to identify anomalous billing patterns, predict emerging fraud schemes, and accelerate the detection process. The sheer volume of claims data processed by CMS presents an ideal environment for such technologies to uncover subtle indicators of fraudulent activity that might elude traditional methods.
Data-Driven Approaches: Beyond just tools, CMS seeks input on holistic, data-driven strategies that can integrate various data sources—claims data, enrollment data, provider histories, enforcement actions—to create a more comprehensive picture of potential fraud risks. The goal is to move towards a predictive model of fraud prevention rather than a reactive one.
Expanding Pre- and Post-Payment Review: The RFI suggests an interest in intensifying both pre-payment (reviewing claims before payment is issued) and post-payment (auditing claims after payment) review processes. While these reviews are already part of CMS’s toolkit, the agency is likely considering more frequent, targeted, and sophisticated application of these mechanisms, particularly for high-risk services like genetic testing.
Accelerating Fraud Detection Earlier in the Reimbursement Claims Lifecycle: A crucial objective is to move fraud detection "upstream." Identifying fraudulent claims or providers earlier in the process, ideally before services are even rendered or claims submitted, can prevent significant financial losses and reduce the administrative burden of recovering improperly paid funds. This could involve enhanced vetting during provider enrollment or real-time claims analysis.

The Stark Disparity: Genetic Testing’s Outsized Financial Footprint

The urgency behind the CRUSH initiative, particularly its focus on genetic testing, is underscored by compelling federal data cited by CMS. The agency revealed that in 2024, genetic tests, despite accounting for a mere 5% of the total test volume under Medicare Part B, represented a staggering 43% of the overall laboratory spending. This translates to an approximate expenditure of $3.6 billion on genetic tests alone. This stark disparity—a small volume of tests consuming a disproportionately large share of the budget—raises immediate red flags regarding potential fraud, waste, or abuse.

To contextualize this, consider that routine clinical laboratory tests, such as complete blood counts or lipid panels, account for a vast majority of the test volume but individually carry a much lower unit cost. While legitimate genetic tests can indeed be high-cost due to their complexity, the magnitude of this spending relative to volume suggests that either an exceptionally high number of these expensive tests are being performed, or there is an issue with the medical necessity or billing practices surrounding them. The agency’s concern is further amplified by ongoing enforcement actions and fraud alerts specifically tied to laboratory testing, indicating a persistent problem that current oversight mechanisms may not be fully addressing.

The financial implications of this imbalance are substantial. A significant portion of the $3.6 billion, if indeed attributable to fraudulent or medically unnecessary tests, represents a direct drain on taxpayer dollars. Beyond the monetary loss, there are broader consequences:

Diversion of Resources: Funds allocated to fraudulent schemes are diverted from legitimate healthcare services, potentially impacting access to care or investment in other critical areas.
Patient Harm: Patients subjected to unnecessary genetic tests may experience anxiety, receive misleading information, or even undergo subsequent, unwarranted medical procedures. Furthermore, their personal genetic information, a highly sensitive data type, could be compromised or misused.
Distortion of Healthcare Spending: Inflated spending in one area can skew overall healthcare economics, making it harder to accurately assess and allocate resources across the system.
Erosion of Trust: Widespread fraud undermines public trust in the healthcare system and its providers, making it more challenging for legitimate laboratories to gain acceptance and reimbursement for valuable, innovative tests.

MolDX Under Scrutiny: A Potential Blueprint for Broader Oversight?

Another critical aspect of the RFI for clinical laboratories is CMS’s examination of the Molecular Diagnostic Services (MolDX) program. MolDX, developed by Palmetto GBA, one of Medicare’s Administrative Contractors (MACs), is a program designed to provide consistent coverage and payment policies for molecular diagnostic tests across several MAC jurisdictions. Its primary goal is to promote appropriate utilization and ensure accurate billing for complex molecular tests by requiring laboratories to register their tests and provide comprehensive evidence of analytical validity, clinical validity, and clinical utility.

CMS’s questions about MolDX are probing:

Effectiveness in Fraud Reduction: The agency is seeking feedback on whether MolDX registration genuinely reduces fraud risk. This query suggests CMS is evaluating the program’s efficacy and considering whether its model could be scaled or adapted.
Payer Requirements Beyond Jurisdiction: CMS is also interested in why some private payers and even other MACs require participation in MolDX even when a laboratory operates outside a MolDX-designated jurisdiction. This observation hints at MolDX’s perceived value beyond its official boundaries and raises the possibility of its broader adoption or the integration of its principles into new, national requirements for molecular test oversight.

The implications of CMS’s intense interest in MolDX are significant. It could signal:

Nationalization of MolDX Principles: CMS might consider implementing MolDX-like registration and evidence-based review processes on a national scale, either through a new federal program or by expanding MolDX’s reach.
Stricter Test Validation Requirements: Laboratories developing and offering molecular tests could face more stringent requirements for demonstrating the medical necessity, analytical validity, and clinical utility of their assays, mirroring MolDX’s rigorous review process.
Increased Administrative Burden: While intended to streamline, a broader MolDX-like framework could increase the administrative burden on laboratories, particularly smaller entities, requiring significant investment in documentation and compliance.
Impact on Innovation: While fraud prevention is crucial, overly burdensome regulations could inadvertently stifle innovation by making it more challenging for legitimate, novel tests to gain market access and reimbursement.

The Chronology of Engagement and Future Steps

The timeline for the CRUSH initiative began with the publication of the Request for Information (RFI) on February 27, 2026, in the Federal Register. This formal announcement initiated a public comment period, which concluded on March 30, 2026. This relatively short window underscored the urgency CMS places on addressing the issues outlined in the RFI.

Following the close of the comment period, the process typically unfolds as follows:

Analysis of Feedback: CMS staff will meticulously review and analyze all submitted comments. This involves categorizing feedback, identifying common themes, assessing the feasibility of proposed solutions, and noting any significant concerns raised by stakeholders.
Internal Deliberation and Policy Development: Based on the RFI feedback and its own internal assessments, CMS will begin to develop specific policy proposals. This phase often involves collaboration with various internal departments, legal counsel, and potentially external experts.
Drafting Proposed Rules: Once initial policy directions are established, CMS will draft a Notice of Proposed Rulemaking (NPRM). This document, which will be published in the Federal Register, will detail specific regulatory changes, their rationale, and their anticipated impact.
Second Public Comment Period: The NPRM will trigger another public comment period, typically longer than the RFI period, allowing stakeholders to provide more targeted feedback on the specific proposed rules. This is another crucial opportunity for laboratories to influence the final regulations.
Final Rule Publication: After considering feedback on the NPRM, CMS will issue a Final Rule, which will officially amend regulations and take effect on a specified date. This entire process, from RFI to Final Rule, can often take 18-24 months or longer, depending on the complexity and scope of the changes.

Anticipated Reactions and Broader Implications

The CRUSH RFI has undoubtedly elicited a range of reactions from various stakeholders across the healthcare ecosystem.

Clinical Laboratory Industry: Industry associations, such as the American Clinical Laboratory Association (ACLA), the College of American Pathologists (CAP), and the Association for Diagnostics & Laboratory Medicine (ADLM), likely welcomed CMS’s proactive engagement in addressing fraud while simultaneously expressing concerns about potential over-regulation. Their feedback would have emphasized the need for targeted policies that distinguish between fraudulent actors and legitimate laboratories, advocating for clear, actionable guidelines that do not stifle innovation or create undue administrative burdens for compliant entities. Individual laboratory executives and compliance leaders would have provided detailed operational insights, data on the costs of compliance, and suggestions for fraud detection that are practical and effective in a real-world lab setting.
Patient Advocacy Groups: These organizations would generally support measures aimed at protecting patients from unnecessary testing, fraudulent billing, and the misuse of sensitive genetic data. They would likely advocate for transparency, informed consent, and safeguards to ensure that legitimate, medically necessary genetic tests remain accessible.
Healthcare Providers (Physicians): While not the primary target, physicians who order genetic tests would be interested in ensuring that any new regulations do not impede their ability to access necessary diagnostic tools for their patients or create excessive documentation requirements that detract from patient care.
Law Enforcement and Anti-Fraud Entities: These groups would likely commend CMS’s initiative, seeing it as a vital step in strengthening the tools available to combat sophisticated healthcare fraud schemes. They might advocate for stronger penalties and enhanced data-sharing capabilities to improve investigative outcomes.

The broader implications of the CRUSH initiative are significant and far-reaching:

Increased Compliance Burden: Clinical laboratories, especially those performing high-cost genetic and molecular testing, should anticipate an increased focus on compliance. This will necessitate investments in robust internal compliance programs, enhanced documentation practices, and possibly new staff roles dedicated to regulatory affairs and analytics.
Shift in Reimbursement Landscape: The RFI signals a potential shift towards more rigorous pre- and post-payment reviews, stricter enrollment criteria, and potentially new requirements for test validation and medical necessity documentation. This could impact reimbursement rates, claims processing times, and the overall financial viability of certain tests.
Technological Adoption: Laboratories will need to consider adopting more sophisticated internal data analytics tools to mirror CMS’s capabilities, enabling them to proactively identify and address potential billing anomalies or compliance risks within their own operations.
Impact on Innovation: While fraud prevention is paramount, there is always a delicate balance between regulation and innovation. The industry will closely watch to ensure that new rules do not inadvertently create barriers for legitimate, groundbreaking genetic technologies that could offer significant patient benefits.
Enhanced Program Integrity: Ultimately, if successful, the CRUSH initiative aims to create a more resilient and secure federal healthcare system, reducing financial losses to fraud and ensuring that healthcare dollars are spent on medically necessary services for beneficiaries.

The closing of the RFI comment period marks merely the end of the initial fact-gathering stage. For clinical laboratories and other stakeholders, the imperative now shifts to closely monitoring CMS’s next steps, preparing for future proposed rules, and continuing to engage constructively in the rulemaking process to help shape a regulatory environment that effectively combats fraud without unduly burdening legitimate healthcare providers and innovators. The coming months and years will undoubtedly see significant changes in how genetic testing is overseen and reimbursed, underscoring the critical importance of industry vigilance and proactive engagement.